Vectura Group PLC (LON:VEC)‘s stock had its “hold” rating reaffirmed by Peel Hunt in a research report issued to clients and investors on Wednesday. They presently have a GBX 160 ($2.07) price objective on the stock. Peel Hunt’s target price would indicate a potential upside of 67.01% from the stock’s current price.

Several other brokerages also recently weighed in on VEC. N+1 Singer reaffirmed a “hold” rating on shares of Vectura Group PLC in a research note on Thursday, June 29th. Numis Securities Ltd reaffirmed a “buy” rating on shares of Vectura Group PLC in a research note on Monday, May 22nd. Shore Capital reaffirmed a “buy” rating on shares of Vectura Group PLC in a research note on Wednesday, August 16th. J P Morgan Chase & Co reduced their target price on Vectura Group PLC from GBX 240 ($3.10) to GBX 210 ($2.71) and set an “overweight” rating for the company in a research note on Friday, May 12th. Finally, Panmure Gordon reaffirmed a “buy” rating on shares of Vectura Group PLC in a research note on Wednesday, August 30th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of GBX 209 ($2.70).

Shares of Vectura Group PLC (LON:VEC) traded up 6.50% during midday trading on Wednesday, reaching GBX 95.80. 1,945,108 shares of the company’s stock were exchanged. Vectura Group PLC has a one year low of GBX 88.90 and a one year high of GBX 166.97. The company’s 50-day moving average is GBX 110.07 and its 200-day moving average is GBX 127.61. The stock’s market cap is GBX 649.19 million.

Vectura Group PLC (LON:VEC) last announced its earnings results on Tuesday, September 5th. The company reported $0.04 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.02. Vectura Group PLC had a negative return on equity of 11.44% and a negative net margin of 48.35%. Equities analysts expect that Vectura Group PLC will post $4.72 earnings per share for the current fiscal year.

WARNING: This article was first posted by American Banking News and is the property of of American Banking News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at

In other news, insider Andrew Derodra purchased 82,000 shares of the company’s stock in a transaction that occurred on Thursday, September 7th. The stock was purchased at an average cost of GBX 90 ($1.16) per share, for a total transaction of £73,800 ($95,311.89).

About Vectura Group PLC

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group PLC (LON:VEC)

Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with's FREE daily email newsletter.